Trials / Completed
CompletedNCT03461146
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-6548 | Oral tablet |
Timeline
- Start date
- 2018-03-05
- Primary completion
- 2018-12-03
- Completion
- 2018-12-17
- First posted
- 2018-03-09
- Last updated
- 2026-04-06
- Results posted
- 2021-05-07
Locations
16 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03461146. Inclusion in this directory is not an endorsement.